MNDL Bio Overview
MNDL Bio's solution focuses on optimizing gene expression in cells to significantly increase protein production yield. Leveraging cutting-edge technology, including advanced algorithms and patented methods, the core technology utilizes Artificial Intelligence (AI) and Machine Learning (ML) based on genomic Big Data. MNDL enhances the efficiency of biological systems, making them more productive and cost-effective. This has far-reaching applications across various sectors. The company won the "Coller Startup Competition" for Edition 2023.
Cumulative Funding Raised Over Time ($)
$2.0MJan 2024
Latest News
Intel-backed accelerator kicks off first cohort for Ignite startup program in Israel
MNDL Bio wins award for the most innovative biotech solution in the Middle East
growth-positive
The company has raised a total of $2 million for its AI-powered gene optimization platform
MNDL Bio, an Israeli company specializing in AI-powered gene optimization, has raised $2 million in a pre-seed funding round led by Earth & Beyond Ventures and IIA, with participation from CPT Capital. The company aims to revolutionize synthetic biology by offering a computational platform that accelerates development timelines, reduces costs, and increases the probability of success. The funding will be used to enhance R&D capabilities, develop a SaaS platform, and expand commercial growth initiatives. The company is poised to capture a significant share of the growing synthetic biology market, which is projected to reach $116 billion by 2032.
InvestmentExpand
growth-positive
Israel’s MNDL Bio is taking on a $116 billion market | CTech
MNDL Bio, an Israeli company, is revolutionizing the synthetic biology sector with its AI-powered gene optimization platform. The company recently raised $2 million in a pre-seed investment round led by Earth & Beyond Ventures and IIA, with participation from CPT Capital. This funding will be used to enhance their algorithmic capabilities, expand their platform, and drive commercial growth. MNDL Bios technology aims to streamline R&D processes, reduce costs, and increase success rates in gene expression optimization. The company is poised to capture a significant share of the growing synthetic biology market, which is projected to reach $116 billion by 2032.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.1M |
| Last funding | $2M |
| Stage | Pre-Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.mndl.bio |
Locations
Herzliya, Israel
Photos & Videos
No files yet
MNDL Bio Business
Business models
B2B
Product stage
Alpha
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringClimate TechClean Industry Tech Sustainable Materials & CircularityTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsIndustrial ManufacturingProcess IndustriesPlasticsChemicals & PetrochemicalsEnergy, Utilities & Waste ManagementNew FuelsBiofuelsWaste Treatment, Environmental Services & RecyclingAgriculture & FoodLivestockCore Technology
BiologicalsGenesTags (4)
climate-techbiotechnologygene-editingbiofuelMNDL Bio Financials
$2.1M
Total funding
Undisclosed
Capital raised
$2M
Last funding
Pre-Seed
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$2.0MJan 2024
Private Equity Funding
Pre-Seed
Jan 2024
$2M
Earth & Beyond Ventures (Lead)
,
CPT Capital
Non-Equity Funding
GrantEvent
Jul 2023
$100K
COLLER Startup Competition
MNDL Bio Lifecycle
Cumulative Funding Raised Over Time
$2.0MJan 2024
All Events
Pre-Seed
Jan 2024
$2M
Earth & Beyond Ventures (Lead)
,
CPT Capital
GrantEvent
Jul 2023
$100K
COLLER Startup Competition
MNDL Bio News
4 articlesIntel-backed accelerator kicks off first cohort for Ignite startup program in Israel
MNDL Bio wins award for the most innovative biotech solution in the Middle East
growth-positive
The company has raised a total of $2 million for its AI-powered gene optimization platform
MNDL Bio, an Israeli company specializing in AI-powered gene optimization, has raised $2 million in a pre-seed funding round led by Earth & Beyond Ventures and IIA, with participation from CPT Capital. The company aims to revolutionize synthetic biology by offering a computational platform that accelerates development timelines, reduces costs, and increases the probability of success. The funding will be used to enhance R&D capabilities, develop a SaaS platform, and expand commercial growth initiatives. The company is poised to capture a significant share of the growing synthetic biology market, which is projected to reach $116 billion by 2032.
InvestmentExpand
growth-positive
Israel’s MNDL Bio is taking on a $116 billion market | CTech
MNDL Bio, an Israeli company, is revolutionizing the synthetic biology sector with its AI-powered gene optimization platform. The company recently raised $2 million in a pre-seed investment round led by Earth & Beyond Ventures and IIA, with participation from CPT Capital. This funding will be used to enhance their algorithmic capabilities, expand their platform, and drive commercial growth. MNDL Bios technology aims to streamline R&D processes, reduce costs, and increase success rates in gene expression optimization. The company is poised to capture a significant share of the growing synthetic biology market, which is projected to reach $116 billion by 2032.
InvestmentExpand
MNDL Bio Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 8 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 21 classification IDs that could be used for matching.
MNDL Bio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Ortal Wein |
| Registrar ID | 516889235 |
| Phone | +972544595111 |
| Creator | Ortal Wein |
| Creator email | ortalw@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-10-09T00:00:00.000Z |
| Created | 2023-07-16T00:00:00.000Z |
| Claimed | Yes |